Location Greater Boston Area, United States, North America Regions East Coast, New England Gender Male
LinkedIn View on LinkedIn
Louis Brenner, President and Chief Executive Officer of Allena Pharmaceuticals.
Prior to joining Radius, he served as Senior Vice President at AMAG Pharmaceuticals, where he was responsible for the Phase 3 studies and the successful regulatory submission for Feraheme®.
Before that, he served in progressively senior roles at Genzyme, where he
advanced the development and commercialization of products to treat metabolic bone disease.He is the co-inventor of the formulation for Renvela®, an oral phosphate binder to treat hyperphosphatemia, and lead the acquisition of Bone Care International, manufacturer of Hectorol®, a synthetic Vitamin D analog for the treatment of hyperparathyroidism.
He also previously served as a Director of PLC Medical Systems. Dr. Brenner is board-certified in Nephrology and cares for patients at Brigham and Women's Hospital in Boston, and is a lecturer in Medicine at Harvard Medical School.
He received a BS in Biology from Yale University, an MD from Duke University, and an MBA from Harvard Business School.
